For real-time stability monitoring, all four WHO BCG RRs of BCG vaccines were used (NIBSC code: 07/270, 07/272, 07/274, 10/272). The BCG Moreau-RJ samples were sent to 16 participants in 13 different countries. These include 7 BCG vaccine manufacturers and 9 national control laboratories worldwide. Fifteen of the participating laboratories RAD001 ic50 agreed to perform the cultural viable count assay for the estimation of CFU, 10 agreed to perform the modified ATP assay and 13 agreed to perform the mPCR assay. All participants are experienced in cultural viable count assay for lyophilized

BCG preparations but familiarity with the modified ATP and mPCR assays is varied. Many of the participants have been involved in a previous collaborative study which involved the use of these techniques. For this report, a code inhibitors number was allocated at random to each participant, not necessarily representing the order of the participant list (Appendix I). Participants were requested to test 10 ampoules of BCG Moreau-RJ

vaccine preparation in their established routine in-house method for the cultural viable count assay, 10 ampoules in the modified ATP assay and 2 ampoules in the mPCR assay. For the cultural viable count assay the study design recommended the 10 ampoules of BCG sample should be tested in at least two to three independent experiments using different batches of solid medium preparation. No pooling of reconstituted BCG ampoules was permitted for this study and each ampoule was tested individually. Three 1:2 serial dilutions (with the optimal dilution as the middle of the serial see more dilutions) were prepared from each reconstituted ampoule. Each diluted suspension was tested in triplicate, resulting in three readings per dilution and a total of nine readings Dichloromethane dehalogenase per ampoule. After approximately 21 days incubation at 37 °C the average CFU counts were calculated, recorded and sent to NIBSC for collation and statistical analysis. Laboratories participating in the modified ATP assay estimated the content of ATP in 10 lyophilized BCG Moreau RJ samples following the protocol provided. The 10 ampoules

of BCG were tested in at least two to three independent experiments, as in the cultural viable count assay. Lyophilized BCG samples were reconstituted with 1 ml Dubos medium (SSI Diagnostica, Denmark) or other suitable culture medium; and the BCG suspensions were incubated at 37 °C for 22–26 h. Three 1:2 serial dilutions were prepared from each overnight BCG culture in pre-warmed medium (undiluted, 1:2 and 1:4). The procedures of ATP extraction and estimation were the same as described previously [10]. Results were recorded and data sent to NIBSC for collation and statistical analysis. Participants were requested to use their own in-house method to extract and purify DNA from two ampoules of BCG Moreau-RJ samples to be used in two independent mPCR assays. The mPCR assay protocol was provided to all participants and as described previously [9].